Recruiting NA INTERVENTIONAL 3-arm NCT06357806

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

The Safety and Efficacy of PD-1 Antibody Combined With Pegylated Interferon-α Therapy to Promote the Clinical Cure in Nucleoside (Acid) Analogues-suppressed Chronic Hepatitis B Patients: A Protocol for the Prospective Pilot Study

Sponsor: Beijing 302 Hospital

Conditions Chronic Hepatitis B

Interventions NAs Peg-IFNα-2b Sintilimab

Updated 4 times since 2024 Last updated: Jun 11, 2024 Started: Jun 6, 2024 Primary completion: Dec 5, 2025 Completion: Dec 5, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06357806, this NA trial focuses on Chronic Hepatitis B and remains actively recruiting participants. Sponsored by Beijing 302 Hospital, it has been updated 4 times since 2024, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jun 2024 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
May 2024 — Jun 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing 302 Hospital

Data source: Beijing 302 Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China